|
|
Volumn 134, Issue 5 II, 1997, Pages
|
|
Antiplatelet therapy: Do the new platelet inhibitors add significantly to the clinical benefits of aspirin?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE;
ACETYLSALICYLIC ACID;
ANTITHROMBOCYTIC AGENT;
CLOPIDOGREL;
DAZOXIBAN;
DIPYRIDAMOLE;
EPTIFIBATIDE;
HIRUDIN;
KETANSERIN;
LAMIFIBAN;
RIDOGREL;
RO 449996;
SYNTHETIC PEPTIDE;
THROMBIN;
THROMBIN INHIBITOR;
THROMBOXANE A2;
TICLOPIDINE;
TIROFIBAN;
UNCLASSIFIED DRUG;
VON WILLEBRAND FACTOR;
ACUTE HEART INFARCTION;
ANGINA PECTORIS;
ANTICOAGULANT THERAPY;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
CORONARY ARTERY DISEASE;
DRUG COST;
HUMAN;
ISCHEMIC HEART DISEASE;
MAJOR CLINICAL STUDY;
META ANALYSIS;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
THROMBOCYTE AGGREGATION INHIBITION;
THROMBOSIS PREVENTION;
|
|
EID: 0031456834
PISSN: 00028703
EISSN: None
Source Type: Journal
DOI: 10.1016/s0002-8703(97)80051-8 Document Type: Conference Paper |
|
Times cited : (20)
|
|
References (53)
|
